Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 50Terminated 6Unknown 5Active not recruiting 2No longer available 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Prostatic Neoplasms 26Lymphoma, Large B-Cell, Diffuse 15Lymphoma 14Burkitt Lymphoma 10Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Hodgkin Disease 6Lymphoma, Non-Hodgkin 4Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Melanoma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, AIDS-Related 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Immunoblastic Lymphadenopathy 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Skin Neoplasms 1Rasmussen subacute encephalitis 1Prostate Cancer, Hereditary, 7 1

Interventions

Dexamethasone 117Lenalidomide 77daratumumab 59Bortezomib 54carfilzomib 41Calcium Dobesilate 36pomalidomide 35Cyclophosphamide 27isatuximab 23belantamab mafodotin 22Specimen Handling 20Biopsy 20Magnetic Resonance Spectroscopy 17dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 12Melphalan 12selinexor 11ixazomib 11iberdomide 11fludarabine 11elotuzumab 11fludarabine phosphate 8talquetamab 7X-Rays 7trametinib 6nirogacestat 6venetoclax 5Thalidomide 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Multiple Myeloma × Prednisone × Clear all
NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT03829371 2025-12-03

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

University of Turin, Italy

Phase 4 Active not recruiting
450 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡